Climb Bio Total Liabilities and Share Holders Equity 2021-2024 | CLYM

Climb Bio total liabilities and share holders equity from 2021 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

Climb Bio Total Liabilities and Share Holders Equity 2021-2024 | CLYM

Climb Bio total liabilities and share holders equity from 2021 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.4B
Vertex Pharmaceuticals (VRTX)$125.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$106.8B
Gilead Sciences (GILD)$105.9B
CSL (CSLLY)$97.5B
GSK (GSK)$81.1B
Alnylam Pharmaceuticals (ALNY)$36.4B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.6B
Biogen (BIIB)$27.9B
Illumina (ILMN)$23.7B
Moderna (MRNA)$22.2B
BeiGene (BGNE)$22.1B
Genmab (GMAB)$15.7B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$13.1B
Insmed (INSM)$12.9B
Vaxcyte (PCVX)$12.6B
Incyte (INCY)$12.6B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.7B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.8B
Revolution Medicines (RVMD)$8.2B
Repligen (RGEN)$8B
Intra-Cellular Therapies (ITCI)$7.8B
Ascendis Pharma (ASND)$7.8B